Compare AbCellera Biologics Inc (ABCL) vs Wipro Limited (WIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Wipro Limited — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Wipro Limited trades at $1.85 (market cap $18.14B). The key difference: Wipro Limited is far larger — about 7.7× AbCellera Biologics Inc's market cap, and Wipro Limited pays a 10.37% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WIT | |
|---|---|---|
Market Cap | $2.35B | $18.14B |
Sector | Health | Technology |
52-Week High | $8.12 | $3.09 |
52-Week Low | $2.78 | $1.82 |
Enterprise Value | $1.99B | $14.53B |
Dividend Yield | — | 10.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
WIT trades at $1.85, down 2.12% today, with a bearish technical signal from moving averages. The company reported revenue of $890.88B in 2025 with a net income margin of 14.25% and a P/E ratio of 13.82. Recent earnings have missed estimates for three consecutive quarters, and analyst sentiment is mixed with a Hold consensus. News highlights include AI partnerships and a weak Q2 2026 revenue outlook.
The outlook is cautious due to near-term revenue pressure and earnings misses, though valuation appears reasonable. Risks include client spending caution and competitive pressures. Upside may depend on AI-driven growth initiatives and large deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
